PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 14709625-0 2004 Potent inhibition of human liver aldehyde oxidase by raloxifene. Raloxifene Hydrochloride 53-63 aldehyde oxidase 1 Homo sapiens 33-49 18424432-7 2008 Administration of the xanthine oxidase (XO) inhibitor oxypurinol or aldehyde oxidase (AO) inhibitor raloxifene significantly decreased NO generation from nitrite in heart or liver. Raloxifene Hydrochloride 100-110 aldehyde oxidase 1 Homo sapiens 68-84 18424432-7 2008 Administration of the xanthine oxidase (XO) inhibitor oxypurinol or aldehyde oxidase (AO) inhibitor raloxifene significantly decreased NO generation from nitrite in heart or liver. Raloxifene Hydrochloride 100-110 aldehyde oxidase 1 Homo sapiens 86-88 16143537-4 2006 The Michaelis-Menten kinetics of aldehyde oxidase and its inhibition by raloxifene and BAU were highly variable between species. Raloxifene Hydrochloride 72-82 aldehyde oxidase 1 Homo sapiens 33-49 14709625-4 2004 However, raloxifene had only small effects on xanthine oxidase, an enzyme related to aldehyde oxidase. Raloxifene Hydrochloride 9-19 aldehyde oxidase 1 Homo sapiens 85-101 14709625-5 2004 In addition, several other compounds of the same therapeutic class as raloxifene were examined for their potential to inhibit aldehyde oxidase. Raloxifene Hydrochloride 70-80 aldehyde oxidase 1 Homo sapiens 126-142 14709625-7 2004 The relevance of these data to the mechanistic understanding of aldehyde oxidase catalysis, as well as to the potential for raloxifene to cause drug interactions with agents for which aldehyde oxidase-mediated metabolism is important, such as zaleplon or famciclovir, is discussed. Raloxifene Hydrochloride 124-134 aldehyde oxidase 1 Homo sapiens 184-200 14709625-3 2004 Raloxifene has also been shown to be a noncompetitive inhibitor of an aldehyde oxidase-catalyzed reduction reaction of a hydroxamic acid-containing compound, with a K(i) of 51 nM. Raloxifene Hydrochloride 0-10 aldehyde oxidase 1 Homo sapiens 70-86 34415167-0 2021 Interrogating the Inhibition Mechanisms of Human Aldehyde Oxidase by X-ray Crystallography and NMR Spectroscopy: The Raloxifene Case. Raloxifene Hydrochloride 117-127 aldehyde oxidase 1 Homo sapiens 49-65 34624627-4 2021 Extensive oxidation rates of BIBX1382 were observed in hepatocytes from humanized liver mice and were suppressed by the typical human AOX1 inhibitors raloxifene and hydralazine. Raloxifene Hydrochloride 150-160 aldehyde oxidase 1 Homo sapiens 134-138 34415167-2 2021 Herein, we employed an integrative approach by combining NMR, X-ray crystallography, and enzyme inhibition kinetics to understand the inhibition modes of three hAOX1 inhibitors-thioridazine, benzamidine, and raloxifene. Raloxifene Hydrochloride 208-218 aldehyde oxidase 1 Homo sapiens 160-165 34415167-4 2021 Additionally, we describe the first crystal structure of hAOX1 in complex with raloxifene. Raloxifene Hydrochloride 79-89 aldehyde oxidase 1 Homo sapiens 57-62 31182423-5 2019 The aldehyde oxidase (AO) inhibitor raloxifene and the xanthine oxidase inhibitor febuxostat inhibited the formation of PF-6870961 in human liver cytosol, suggesting both enzymes were involved in the metabolism of the drug. Raloxifene Hydrochloride 36-46 aldehyde oxidase 1 Homo sapiens 4-20 31289113-1 2019 Tamoxifen, raloxifene, and nafoxidine are selective estrogen receptor modulators (SERMs) reported to inhibit the catalytic activity of human aldehyde oxidase 1 (AOX1). Raloxifene Hydrochloride 11-21 aldehyde oxidase 1 Homo sapiens 141-159 31289113-1 2019 Tamoxifen, raloxifene, and nafoxidine are selective estrogen receptor modulators (SERMs) reported to inhibit the catalytic activity of human aldehyde oxidase 1 (AOX1). Raloxifene Hydrochloride 11-21 aldehyde oxidase 1 Homo sapiens 161-165 31289113-4 2019 The rank order in the potency (based on IC50 values) of AOX1 inhibition by SERMs was raloxifene > bazedoxifene ~ lasofoxifene > tamoxifen > acolbifene. Raloxifene Hydrochloride 85-95 aldehyde oxidase 1 Homo sapiens 56-60 31182423-5 2019 The aldehyde oxidase (AO) inhibitor raloxifene and the xanthine oxidase inhibitor febuxostat inhibited the formation of PF-6870961 in human liver cytosol, suggesting both enzymes were involved in the metabolism of the drug. Raloxifene Hydrochloride 36-46 aldehyde oxidase 1 Homo sapiens 22-24 31182423-6 2019 However, greater inhibition was observed with raloxifene, indicating AO is a dominant enzyme in the biotransformation. Raloxifene Hydrochloride 46-56 aldehyde oxidase 1 Homo sapiens 69-71 28029084-8 2017 Raloxifene, an inhibitor of aldehyde oxidase, markedly decreased the formation of 5-oxo-ZAL by liver cytosol of mice and humans. Raloxifene Hydrochloride 0-10 aldehyde oxidase 1 Homo sapiens 28-44 30209037-6 2018 Metabolite formation was inhibited by the AO inhibitors menadione and raloxifene, but not by the xanthine oxidase inhibitor allopurinol. Raloxifene Hydrochloride 70-80 aldehyde oxidase 1 Homo sapiens 42-44 24824603-6 2014 The role of human AO and XO in the metabolism of 6MP was established using the specific inhibitors raloxifene and febuxostat. Raloxifene Hydrochloride 99-109 aldehyde oxidase 1 Homo sapiens 18-20 24406683-0 2014 Inhibition of xanthine oxidase by the aldehyde oxidase inhibitor raloxifene: implications for identifying molybdopterin nitrite reductases. Raloxifene Hydrochloride 65-75 aldehyde oxidase 1 Homo sapiens 38-54 24406683-5 2014 Likewise, raloxifene, an estrogen receptor antagonist, has been identified as a potent (Ki=1.0 nM) inhibitor of AO. Raloxifene Hydrochloride 10-20 aldehyde oxidase 1 Homo sapiens 112-114